We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Biomea Fusion Inc is a preclinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of irreversible small molecule drugs to treat patients with genetically defined cancers. The company's lead product candidate, BMF-219, is designed to be an orally bi... Biomea Fusion Inc is a preclinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of irreversible small molecule drugs to treat patients with genetically defined cancers. The company's lead product candidate, BMF-219, is designed to be an orally bioavailable, potent and selective irreversible inhibitor of menin, an important transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers. Show more
Ask ADVFN Intelligence (AI)
Icovamenib & BMF-650 (oral small molecule GLP-1) are the cornerstones of the metabolic franchiseBiomea preparing icovamenib for late-stage clinical development2025 corporate update to be...
New in vivo preclinical data announced today, demonstrate that icovamenib, in combination with semaglutide showed additional 11.5% body weight reduction and 43% increase in lean muscle mass...
REDWOOD CITY, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing oral...
Icovamenib met the primary endpoint, displaying a meaningful statistically significant placebo-corrected mean reduction in HbA1c in the prespecified per protocol patient populationBest response...
REDWOOD CITY, Calif., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing oral...
In preclinical experiments, icovamenib enhanced beta cell function and responsiveness of human islets to GLP-1-based therapies. These effects were associated with an increase in the expression...
Preliminary data supports BMF-500’s potential as a transformative therapy for patients with FLT3 mutated relapsed or refractory (R/R) acute leukemiaBMF-500 showed a favorable safety and...
| Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.35 | 8.92857142857 | 3.92 | 4.59 | 3.8 | 620441 | 4.29285688 | CS |
| 4 | 0.37 | 9.48717948718 | 3.9 | 4.59 | 3.64 | 787981 | 4.05910854 | CS |
| 12 | -4.63 | -52.0224719101 | 8.9 | 9.25 | 3.64 | 848105 | 5.26592578 | CS |
| 26 | -1.24 | -22.5045372051 | 5.51 | 13.07 | 3.64 | 842759 | 7.0696796 | CS |
| 52 | -12.48 | -74.5074626866 | 16.75 | 20.21 | 3.64 | 993857 | 9.14570602 | CS |
| 156 | -2.36 | -35.5957767722 | 6.63 | 43.69 | 2.84 | 656423 | 14.44799062 | CS |
| 260 | -15.73 | -78.65 | 20 | 43.69 | 2.84 | 549152 | 14.34380215 | CS |
Monksdream
5 months ago
Zraced1
8 months ago
giveit2me
1 year ago
Invest-in-America
2 years ago
Invest-in-America
2 years ago
TheFinalCD
2 years ago
Invest-in-America
2 years ago
Bbradley8
2 years ago
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
